Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus

European Journal of Pediatrics

Volumn 176, Issue 7, 2017, Pages 891-897

  Buchs, Clélia ^a   Dalphin, Marie Laure ^b   Sanchez, Stéphane ^c   Perceval, Marie ^a   Coutier, Laurianne ^a   Mainguy, Catherine ^a   Kassaï Koupaï, Behrouz ^d,e   Reix, Philippe ^a,e  

^a HOSPICES CIVILS DE LYON   (France)

^b Centre de ressources et de compétences de la mucoviscidose   (France)

^c CENTRE HOSPITALIER DE TROYES   (France)

^d Centre d'Investigation Clinique   (France)

^e UMR5558   (France)

Author keywords

Cystic fibrosis; Infants; Palivizumab; Pseudomonas aeruginosa; Staphylococcus aureus; Toddlers

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; BACTERIUM ISOLATION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FEMALE; HEALTH CARE; HUMAN; INFANT; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; AGE; COMPLICATION; DRUG ADMINISTRATION; FOLLOW UP; INTRAMUSCULAR DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; PSEUDOMONAS INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

AGE FACTORS; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; PALIVIZUMAB; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 85019181495     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-017-2926-8     Document Type: Article

References (14)

1. American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415–420
2. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD (1998) Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 26:371–379
3. Cohen A, M. Boron, and C. Dingivan (2005) A phase IV study of the safety of Synagis (R) (palivizumab) for prophylaxis of respiratory syncitial virus disease in children with cystic fibrosis. American Thoracic Society Abstracts:A178
4. Collinson J, Nicholson KG, Cancio E, Ashman J, Ireland DC, Hammersley V, Kent J, O’Callaghan C (1996) Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51:1115–1122
5. Dijkema JS, van Ewijk BE, Wilbrink B, Wolfs TF, Kimpen JL, van der Ent CK (2016) Frequency and duration of rhinovirus infections in children with cystic fibrosis and healthy controls: a longitudinal cohort study. Pediatr Infect Dis J 35:379–383
6. Giusti R (2009) North American synagis prophylaxis survey. Pediatr Pulmonol 44:96–98
7. Groves HE, Jenkins L, Macfarlane M, Reid A, Lynn F, Shields MD (2016) Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Pediatr Pulmonol 51:379–385
8. Linnane B, Kiernan MG, O’Connell NH, Kearse L, Dunne CP (2015) Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidiscip Respir Med 10:32
9. Mitchell I, Paes BA, Li A, Lanctot KL, investigators C (2011) CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 30:651–655
10. Robinson KA, Odelola OA, Saldanha IJ (2016) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 7:CD007743
11. Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL, Group ES (2012) Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros 11:446–453
12. Van Ewijk BE, Wolfs TF, Aerts PC, Van Kessel KP, Fleer A, Kimpen JL, Van der Ent CK (2007) RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61:398–403
13. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Tiddens HA, Investigators AS (2011) Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 306:163–171
14. Winterstein AG, Eworuke E, Xu D, Schuler P (2013) Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol 48:874–884